CSDB: Search results

Taxonomic group: protista / Euglenozoa (Phylum: Euglenozoa)
Host organism: Homo sapiens
Organ / tissue: Life stage: trypomastigote
Associated disease: Chagas disease [ICD11: 1F53

, ICD11: XN56V

]; infection due to Trypanosoma cruzi [ICD11: XN56V

]

The structure was elucidated in this paper
NCBI PubMed ID: 30868536
Publication DOI: 10.1007/978-1-4939-9148-8_22
Journal NLM ID: 9214969
Publisher: Springer
Correspondence: icalmeida

utep.edu
Institutions: Department of Biological Sciences, University of Texas at El Paso, El Paso, TX, USA, Department of Chemistry and Biochemistry, University of Texas at El Paso, El Paso, TX, USA, Barcelona Institute for Global Health (ISGlobal), Hospital Clinic - Universitat de Barcelona, Barcelona, Spain, Barcelona Centre for International Health Research (ISGlobal), Barcelona, Spain, Facultad de Medicina, Instituto de Medicina Tropical, Universidad Central de Venezuela, Caracas, Venezuela, Faculty of Medicine, Universidad Mayor de San Simon, Cochabamba, Bolivia, Fundación CEADES, Cochabamba, Bolivia

Chagas disease (ChD), caused by the protozoan parasite Trypanosoma cruzi, affects millions of people worldwide. Chemotherapy is restricted to two drugs, which are partially effective and may cause severe side effects, leading to cessation of treatment in a significant number of patients. Currently, there are no biomarkers to assess therapeutic efficacy of these drugs in the chronic stage. Moreover, no preventive or therapeutic vaccines are available. In this chapter, we describe the purification of Trypanosoma cruzi trypomastigote-derived glycosylphosphatidylinositol (GPI)-anchored mucins (tGPI-mucins) for their use as antigens for the reliable primary or confirmatory diagnosis and as prognostic biomarkers for early assessment of cure following ChD chemotherapy. We also describe, as an example, the synthesis of a potential tGPI-mucin-derived α-Gal-terminating glycan and its coupling to a carrier protein for use as diagnostic and prognostic biomarker in ChD.

neoglycoproteins, Trypanosoma cruzi, diagnosis, biomarkers, mucins, Chagas disease, anti-α-Gal antibodies, carbohydrate synthesis, chemiluminescent enzyme-linked immunosorbent assay, chemotherapy

Structure type: structural motif or average structure
Location inside paper: p. 289, Fig. 1
Aglycon: Thr
Trivial name: mucin oligosaccharide, tGPI-mucin
Compound class: O-glycan
Contained glycoepitopes: IEDB_131186,IEDB_135818,IEDB_136044,IEDB_136906,IEDB_137340,IEDB_137472,IEDB_140108,IEDB_141794,IEDB_141807,IEDB_151528,IEDB_151531,IEDB_167072,IEDB_190606,IEDB_241097,IEDB_742245,SB_165,SB_166,SB_187,SB_195,SB_30,SB_7,SB_88

Methods: chemical synthesis, MALDI-TOF MS, enzymatic digestion, extraction, LC-MS, conjugation, immunoreactivity assays, CL-ELISA

Related record ID(s): 7357, 8280, 8281, 8283
NCBI Taxonomy refs (TaxIDs): 5693
Show glycosyltransferases

There is only one chemically distinct structure:

CC(=O)N[C@H]1[C@@H](O)O[C@H](CO[C@@H]2O[C@H](CO)[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)[C@H]2O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O[C@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@@H]1O

SVG MW SMILES 3D mol Ionize